-
Bone Therapeutics, Rigenerand Ink Cell Therapy Deal
contractpharma
January 20, 2021
Bone Therapeutics, a cell therapy company addressing unmet medical needs in orthopedics and other diseases, and Rigenerand SRL, a biotech company that both develops and manufactures medicinal products for cell therapy applications, primarily for ...
-
Immuneel sets up cell therapy development and production facility in Narayana Hrudayalaya Health City, Bengaluru
expresspharma
January 19, 2021
The facility will currently focus on autologous cell therapies including CAR-T cell therapy for lymphomas and leukaemias.
-
Gracell Biotechnologies Announces Presentation of First-in-Human Data of GC012F a First-in-Class FasTCAR-enabled Dual-targeting BMCA/CD19 CAR-T Cell Therapy for Patients with Relapsed or Refractory Mu
prnasia
December 07, 2020
Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced an interim readout to evaluate the safety and efficacy of ...
-
Regenerative medicine market to reach $16.4 bn in 2026: GlobalData
expresspharma
December 07, 2020
There are currently 53 marketed RM products and 175 RM pipeline agents in development in the eight major markets.
-
Catalent completes acquisition of Bone Therapeutics’ cell therapy manufacturing subsidiary SCTS
expresspharma
November 17, 2020
Catalent Pharma Solutions has completed the acquisition of Bone Therapeutics’ manufacturing subsidiary, Skeletal Cell Therapy Support SA (SCTS), announced on 29 October 2020.
-
Leading Cell Therapy Company JW Therapeutics Lists on Main Board of HKEX
prnasia
November 04, 2020
JW Therapeutics today celebrates the initial public offering (IPO) on the Main Board of the Stock Exchange of Hong Kong, S.A.R., China Limited.
-
CARsgen Therapeutics Closes a USD 186 Million Series C Equity Financing to Accelerate Global Clinical Trials of its Cell Therapy Product Candidates
prnasia
November 04, 2020
CARsgen Therapeutics Holdings Limited, a leading biotechnology company focused on innovation and development of chimeric antigen receptor (CAR) T-cell therapeutics, announced the completion of a USD 186 million Series C Equity Financing.
-
iBio Enters into Agreement with Safi Biosolutions
contractpharma
October 10, 2020
iBio, a biotech innovator and biologics contract manufacturing organization (CMO), has entered into a Master Services Agreement (MSA) with Boston-based Safi Biosolutions to evaluate iBio’s FastPharming System for the expression of key proteins to be ...
-
FDA Approves Study to Investigate Cell Therapy to Treat COVID-19 Related MIS-C
americanpharmaceuticalreview
September 23, 2020
The Cura Foundation in collaboration with The Marcus Foundation, Sanford Health and Alliance for Cell Therapy Now, is supporting a clinical trial of human cord tissue mesenchymal stromal cells (hCT-MSC) to treat children with ...
-
T-knife, Catalent Sign Tech Transfer and Mfg. Pact for Cell Therapy
contractpharma
September 22, 2020
Catalent to provide technology transfer and cGMP clinical manufacture of T-knife’s T1367 T-cell receptor program at its site in Gosselies, Belgium.